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Background: Castration-resistant prostate cancer (CRPC) patients have poor prognoses, and docetaxel (DTX) is
among the few treatment options. An accurate risk classification to identify CRPC patient groups for which DTX
would be effective is urgently warranted. The Armstrong risk classification (ARC), which classifies CRPC patients into
3 groups, is superior; however, its usefulness remains unclear, and further external validation is required before
clinical use. This study aimed to examine the clinical significance of the ARC through external validation in
DTX-treated Japanese CRPC patients.
Methods: CRPC patients who received 2 or more DTX cycles were selected for this study. Patients were classified
into good-, intermediate-, and poor-risk groups according to the ARC. Prostate-specific antigen (PSA) responses and
overall survival (OS) were calculated and compared between the risk groups. A multivariate analysis was performed
to clarify the relationship between the ARC and major patient characteristics.
Results: Seventy-eight CRPC patients met the inclusion criteria. Median PSA levels at DTX initiation was 20 ng/mL.
Good-, intermediate-, and poor-risk groups comprised 51 (65%), 17 (22%), and 10 (13%) patients, respectively. PSA
response rates ≥30% and ≥50% were 33%, 41%, and 30%, and 18%, 41%, and 20% in the good-, intermediate-, and
poor-risk groups, respectivcixely, with no significant differences (p = 0.133 and 0.797, respectively). The median OS in
the good-, intermediate-, and poor-risk groups were statistically significant (p < 0.001) at 30.1, 14.2, and 5.7 months,
respectively. A multivariate analysis revealed that the ARC and PSA doubling time were independent prognostic factors.
Conclusions: Most of CRPC patients were classified into good-risk group according to the ARC and the ARC could
predict prognosis in DTX-treated CRPC patients.
Trial registration: University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) number,
UMIN000011969.
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Castration-resistant prostate cancer (CRPC) patients
have poor prognoses. Although many treatment options
have been developed, truly effective ones remain limited
[1-6]. In Japan, the currently available drugs are limited
even further. Predictions and classifications of CRPC pa-
tients’ clinical outcomes and prognoses for the effective
use of the limited treatment options offer prolonged* Correspondence: nknkzhk@jichi.ac.jp
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unless otherwise stated.survival to the patients. In particular, docetaxel (DTX)
[1,2] has been established as effective and has become
widely used in CRPC treatment; however, in some pa-
tients, DTX is ineffective and induces a high incidence of
adverse events. Thus, the development of an accurate risk
classification that can identify the CRPC patient group in
which DTX would be effective is urgently warranted. Al-
though some reports have demonstrated the usefulness of
superior nomograms for predicting prognosis in CRPC pa-
tients [7-9], these nomograms include many investigation
items and are therefore somewhat difficult to implementl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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(ARC), which classifies CRPC patients into 3 groups ac-
cording to 4 risk factors, including visceral metastases, bone
scan progression, significant pain, and anemia (hemoglobin
[Hb] level < 13 g/dL), is also a superior risk classification
because it can be easily used in clinical practice without
reducing the predictive abilities of nomograms and can pre-
dict not only survival but also post-chemotherapy prostate-
specific antigen (PSA) declines and tumor responses [10].
ARC is highly reliable because it was developed from 656
CRPC patients who were administered DTX and was also
internally validated in 333 CRPC patients who were admin-
istered mitoxantrone among the 1006 CRPC patients in the
TAX327 study [1]. Furthermore, ARC was demonstrated to
significantly classify the clinical outcomes of estramustine
phosphate (EMP) treatment in CRPC patients [11].
However, few reports have externally validated ARC in
CRPC patients who were administered DTX. Under exter-
nal validation, risk classifications and nomograms might
be found to have positive [12] or negative [13] effects and,
sometimes, to clarify characteristics at the time of clinical
use [14]. Kawahara et al. [15] reported that CRPC patients
who were administered DTX in 10 or more cycles had fa-
vorable prognosis; in this study, the authors examined
whether ARC would be useful when selecting CRPC pa-
tients who could continue a DTX regimen for 10 or more
cycles. However, the Hb criteria were changed to 10 g/dL
from 13 g/dL, the bone scan progression risk factor was
replaced with alkaline phosphatase (ALP) levels, and the
association between PSA response and ARC was not refer-
enced. Armstrong, the developer of the ARC, externally
validated ARC and the above-mentioned nomograms in
CRPC patients who were administered DTX [16] and indi-
cated the superior but insufficient discriminatory abilities
and necessary improvements of these tools. Thus, the use-
fulness of ARC remains unclear and needs further external
validation before clinical use.
The objective of this study was to examine the clinical
significance of ARC through external validation in DTX-
treated Japanese CRPC patients.
Methods
Patients and treatment
This study was approved by the institutional review board
of Jichi Medical University. The clinical trial was registered
in the University Hospital Medical Information Network
Clinical Trials Registry (UMIN-CTR) UMIN000011969.
Written informed consent to participate in this study was
obtained from all patients. At our institution, patients with
metastatic and/or first treatment-refractory prostate can-
cer (PCa) are treated with androgen deprivation therapy
(ADT). After progressing to CRPC, the patients are princi-
pally treated in the following order: 1) combined androgen
blockade (CAB), 2) anti-androgen withdrawal, 3) anti-androgen substitution, 4) EMP, 5) DTX, 6) dexamethasone,
and 7) best supportive care. These treatments are contin-
ued until disease progression and/or unacceptable toxicity
occurs. Of the CRPC patients who received DTX in our in-
stitution between July 2003 and September 2012, those
who met the following inclusion criteria were eligible for
this study: 1) confirmed histological PCa diagnosis, 2) re-
fractory to ADT with CAB, anti-androgen withdrawal, and
anti-androgen substitution, 3) refractory to EMP, and 4) re-
ceived 2 or more cycles of DTX.
A modified version of the regimen used in the
SWOG9916 study [2] was used as the DTX treatment
protocol [17]. Briefly, DTX (60 mg/m2) was administered
by intravenous drip infusion for 1 hour on day 1, once every
3–4 weeks. Twice-daily EMP (280 mg) was orally adminis-
tered in combination with DTX. EMP could be reduced to
280 mg/day according to the degree of adverse events and,
if already administered before DTX initiation, continued at
the same dose that was administered before DTX treat-
ment. As a premedication, 8 mg of dexamethasone was ad-
ministered by intravenous drip infusion before and after the
DTX treatment. The DTX treatment was continued until
disease progression, unacceptable toxicity, or a patient’s re-
quest for its cessation. Disease progression was defined as
increases in the number of evaluable lesions observed on
imaging tests and/or biological progression characterised by
an elevated serum PSA level of 25% and an absolute in-
crease of 2 ng/mL or higher than the nadir in at least 3 con-
secutive measurements.
Armstrong risk classification
The patients were classified as good-, intermediate-, and
poor-risk according to the ARC, which included the follow-
ing 4 risk factors: visceral metastases, bone scan progres-
sion, significant pain, and anemia (Hb level < 13 g/dL) [10].
Patients with 0 or 1, 2, and 3 or 4 risk factors were classified
as good-, intermediate-, and poor-risk, respectively. The
risk factor of visceral metastases was defined as “presence”
if computed tomography (CT) and/or magnetic resonance
imaging (MRI) were performed at DTX initiation and re-
vealed visible visceral metastases. The risk factor of bone
scan progression was subject to satisfaction that a bone
scan had been performed at DTX initiation, comparable
prior bone scans had also been performed, and progression
or increases in the numbers of hot spots were demon-
strated by these scans. Although significant pain was
defined as a Present Pain Intensity score (PPI) ≥ 2 and/
or an analgesic score (AS) ≥ 10 in the ARC [10], we de-
fined the use of some types of analgesic at DTX initi-
ation as a surrogate measurement of significant pain
because the PPI and AS of the patients in this study
were not measured. The risk factor of anemia was de-
fined as “presence” if the patient met the criteria of Hb
levels < 13 g/dL at DTX initiation.
Table 1 Patient characteristics
(n = 78)
Age (years) 70 (50–88)
PSA at PCa diagnosis (ng/mL) 124.6 (4.7-19523.1)
PSA at DTX initiation (ng/mL) 19.7 (0.6-1053.0)
Time from PCa diagnosis to DTX initiation (months) 37 (4–189)
PSADT (months) 2.4 (0.6-33.9)









Metastatic site, n (%)
Bone 42 (54)




Bone scan progression, n (%)
Yes 15 (19)
No 63 (81)
Pain at baseline, n (%)
Yes 24 (31)
No 54 (69)
Haemoglobin (g/dL) 11.8 (8.4-14.1)
ALP (IU/L) 290 (59–8689)
Prior treatment, n (%)




No. of DTX cycles 5 (2–46)
Abbreviations: PSA, prostate-specific antigen; PCa, prostate cancer; DTX,
docetaxel; PSADT, prostate-specific antigen doubling time; ECOG, Eastern
Cooperative Oncology Group; ALP, alkaline phosphatase. All continuous data
are described in median (range).
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According to the recommendations of the Prostate Cancer
Clinical Trial Working Group [18], PSA responses were
demonstrated in waterfall plot of decreasing PSA rates for
each patient. Decreasing PSA rates were obtained from
the values determined just before DTX initiation and the
lowest PSA values during DTX treatment. Overall survival
(OS) was defined as the period from DTX initiation to
death. When patients were lost to follow-up, OS was con-
sidered up to the last day of confirmed patient survival.
Adverse events were determined according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC)
version 3.
Statistical analysis
PSA responses were compared with a chi-square test. OS
was determined according to the Kaplan-Meier method
and compared with the log-rank test. A multivariate ana-
lysis of OS was performed to compare the prognostic fac-
tors in a Cox proportional hazard analysis. Continuous
data were divided into 2 groups according to median value.
A concordance index (c-index) was estimated as a measure
of the ARC discriminatory index. A c-index of 0.50 repre-
sents random prediction, whereas a c-index of 1.0 repre-




During the study period, 102 CRPC patients received DTX
at our institution, among whom, 78 met the inclusion cri-
teria. The patient characteristics are shown in Table 1. The
median observation period was 24 months (range, 3–74
months). The median number of administered DTX cycles
was 5 (range, 2–46 cycles), and the median DTX adminis-
tration period was 9 months (range, 1–66 months). In
addition, 0, 1, 2, 3, and 4 ARC risk factors were observed
in 9, 42, 17, 9, and 1 patients, respectively. The good-,
intermediate-, and poor-risk groups according to the ARC
included 51 (65%), 17 (22%), and 10 (13%) patients, respect-
ively. CRPC patients with a history of EMP use were 47/51
(92%), 14/17 (82%), and 8/10 (80%) patients in the good-,
intermediate-, and poor-risk groups, respectively, with no
statistically significant difference (p = 0.367). A total of 67
patients (86%) discontinued DTX treatment during the ob-
servation period, of whom 51, 8, 2, 4, and 2 patients discon-
tinued DTX treatment because of disease progression,
adverse events, death, patient request, and other reasons,
respectively. The remaining 11 patients (14%) were still
undergoing DTX treatment during the course of the study.
Armstrong risk classification assessment
Waterfall plots of PSA response according to each ARC risk
group are shown in Figure 1. PSA responses ≥0%, ≥30%,and ≥50% were observed in 48 (62%), 27 (35%), and 18
(23%) of the total patients, respectively. PSA response
rates ≥30% and ≥50% were observed in 33%, 41%, and
30%, and 18%, 41%, and 20% of the good-, intermediate-,
and poor-risk groups, respectively, with no statistically sig-
nificant differences between the groups (p = 0.133 and
0.797, respectively).
a) Total






























































































Figure 1 Waterfall plots of prostate-specific antigen (PSA) responses according to total (a), good-(b), intermediate-(c), and poor-(d) risk
group of Armstrong risk classification.
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Table 2. Regarding the risk factor of anemia, which was
divided into 2 groups according to the relatively high
Hb value of 13 g/dL, the group with Hb levels ≤ 13 g/dL
dominated with 64 patients (82%). There were significant
associations between OS and the risk factors of visceral me-
tastases (p < 0.001), bone scan progression (p < 0.001), and
significant pain (p < 0.001), but not anemia (p = 0.442).
Patient distributions and OS curves according to the
ARC risk groups are shown in Figure 2. The CRPC patients
at our institution were mostly classified as good-risk (65%).
The median OS durations in the good-, intermediate-, and
poor-risk groups were 30.1 months (95% confidence inter-
val [CI]: 17.8–42.5 months), 14.2 months (95% CI: 3.7–Table 2 Univariate analysis for overall survival according to e












≦ 13.0 64 19.5
Abbreviations: CI, confidence interval. *log rank test.24.7 months), and 5.7 months (95% CI: 3.1–8.2 months),
respectively, with statistically significant differences between
the groups (p < 0.001). During the observation period, death
occurred in 39 patients (46%), of whom 18, 14, and 7 were
in the good-, intermediate-, and poor-risk groups, respect-
ively. The c-index was 0.60 for OS, indicating that the ARC
had a modest discriminatory ability in our cohort.
Subgroup analysis
A multivariate analysis was performed to clarify the rela-
tionship between the ARC and the major patient charac-
teristics that are often evaluated in clinical practice. The
following 6 factors at DTX initiation were covariates of
interest: age, PSA level, PSA doubling time (PSADT),ach risk factor of Armstrong risk classification [10]

















risk n median OS (mo) 95% CI
Good 51 30.1 17.8 - 42.5 
Intermediate 17 14.2 3.7 - 24.7 




Figure 2 Overall survival curves according to Armstrong risk classification [10].
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ance status, Gleason score, and ARC. A univariate analysis
conducted with the log-rank test revealed significant associ-
ations between OS and 4 factors (PSA at DTX initiation,
PSADT, ECOG performance status, and ARC). A multivari-
ate analysis with these 4 factors revealed that the ARC and
PSADT were independent prognostic factors (Table 3).Table 3 Univariate and multivariate analysis for overall surviv
Prognostic factor Category n Median(months) Hazard ra
Age (years)
≦ 70 43 17.0 1.00
>70 35 22.7 0.60
PSA at DTX initiation (ng/ml)
≦ 20 39 39.6 1.00
>20 39 12.6 3.44
PSADT (months)
>2.4 38 31.4 1.00
≦ 2.4 40 16.7 2.56
ECOG performance status
≦ 1 68 20.3 1.00
2 10 4.1 3.11
Gleason score
≦ 7 21 31.2 1.00
>8 57 18.2 1.63
Armstrong risk classification
Good 51 30.1 1.00
Intermediate 17 14.2 2.48
Poor 10 5.7 6.58
Abbreviations: CI, confidence interval; PSA, prostate-specific antigen; PSADT, prostat
ALP, alkaline phosphatase. *log rank test. **Cox proportional hazards model.Discussion
We externally validated the ARC in CRPC patients who
were administered DTX in 2 or more cycles and showed
that there were statistically significant differences in OS
among the ARC risk groups. The median OS and 95%
CI for each ARC risk group were similar between the
CRPC patients used for validation in this study (theal of major prognostic factors
Univariate Multivariate




















1.33 0.60 - 2.97 0.487
3.07 - 14.11 3.21 1.17 - 8.80 0.024
e-specific antigen doubling time; ECOG, Eastern Cooperative Oncology Group;
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velop the ARC [10] (the development group). The c-
index for OS was 0.60, indicating that the ARC had a
modest discriminatory ability in the validation group. A
multivariate analysis revealed that the ARC was an inde-
pendent prognostic factor. Thus, the ability of the ARC to
classify and approximately predict the OS of CRPC patients
with certain reproducibility was confirmed, suggesting that
the ARC is useful when predicting prognosis in DTX-
treated CRPC patients. This means that CRPC patients
who are classified into good- and intermediate-risk groups
are recommended for aggressive DTX administration, be-
cause these patients would be expected to experience pro-
longed OS in response to DTX. However, CRPC patients
who are classified as poor-risk should be recommended for
clinical trial participation or other treatments because given
the poor outcomes, these patients would be expected to ex-
perience a limited prognosis despite the use of DTX.
ARC was also reported to be able to classify PSA re-
sponse in CRPC patients, although this system was princi-
pally aimed at classifying OS [10]. We also externally
validated the usefulness of ARC in classifying the PSA re-
sponse of CRPC patients. However, there were no statisti-
cally significant differences in PSA response between the
ARC risk groups. This result was considered to be caused
by the reason that most of CRPC patients in the validation
group had a history of EMP use; the frequency of a history
of EMP use was high in good-risk group (92%) compared
to intermediate-risk (82%) and poor-risk (80%) groups. The
CRPC patients with a history of EMP use showed signifi-
cantly lower PSA response during DTX treatment than
those without a history of EMP use [10]. Thus, considering
that PSA response during DTX treatment are likely to be
low in the CRPC patients with a history of EMP use, our
cohort might not be suitable for validating the usefulness of
ARC in classifying the PSA response of CRPC patients.
This validation study exhibited the following character-
istics with respect to the ARC: the development group
presented with median PSA levels of 110 ng/mL at DTX
initiation. From this group, symptoms and imaging test
items that are often observed after some disease progres-
sion, including bone scan progression [9], significant pain
[20], and visceral metastases [8,21], were identified as risk
factors. However, as the efficacy of DTX was established in
CRPC patients and DTX initiation in patients with low PSA
levels was found to confer better prognosis [9,15,17,21], the
likelihood of initiating DTX at lower PSA levels has in-
creased to a level higher than those reported in the TAX327
and SWOG9916 trials. The validation group presented me-
dian PSA levels of 20 ng/mL at DTX initiation, a lower
value than that of the development group, and possessed
few ARC risk factors; this led to a disproportionate distribu-
tion in which 65% of CRPC patients in the validation group
were classified as good-risk. Thus, the ARC tends to classifymany CRPC patients with low PSA levels as good-risk. At
the comparison of the prognoses and/or treatment re-
sponses of CRPC patients, the ARC would ensure more ac-
curate outcomes while considering the above-mentioned
ARC characteristics.
This study had the following limitations: a retrospective
study design; a small sample size; different patient back-
grounds in the validation and development groups in
terms of EMP exposure, lower PSA levels, lack of visceral
spread, and lower numbers of DTX cycles; and a different
definition of significant pain as a risk factor. Although
these major limitations could have possibly deteriorated
the quality of this external validation study of ARC, it was
noteworthy that the ARC indicated good discriminatory
ability for OS even in this validation group.
Conclusions
Most of CRPC patients were classified into good-risk
group according to the ARC and the ARC could predict
prognosis in DTX-treated CRPC patients.
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